DyNAbind is ready to be your partner for every step of DNA-Encoded Library screening. We pride ourselves in designing customized drug discovery campaigns tailored to your specific project. We’ll be with you every step of the way from initial screen to kinetic hit validation and binder optimization.
At DyNAbind, every project we run is different, uniquely designed to meet a partner’s specific needs.
However, a typical workflow looks like this:
We start by planning the ideal screening campaign for your drug target. Our experienced selection team goes beyond just optimizing screening conditions to also finding the right set of controls and counterscreens to focus discovery efforts on what matters to you. With the right experimental design, we can bias our efforts to locating, e.g. active or allosteric site binders, or already obtain information about binder specificity.
Once selections are performed, our computational chemistry and analytics team goes to work on the data. They’ll take advantage of a deep data analysis pipeline to filter out noise and lock in on the most promising hit compounds. Advanced cheminformatics methods allow us to cluster and visualize the identified chemical space, identifying the most striking compound families and intelligently selecting representative compounds for follow-up.
To help your medicinal chemistry team triage their options and focus only on the most promising candidates, we’ll move ahead to kinetic hit validation. Our proprietary on-DNA biosensor technology lets us screen hit compounds for affinity in your range of interest in only a fraction of the time it would take for conventional large-scale resynthesis and testing. With dissociation constants, on-rates and off-rates, your team can easily pick the most exciting compounds for further development.
From there, we’re still available to offer additional support with compound provision, fragment-linking
or whatever it takes to help us achieve success together.
At DyNAbind, every project we run is different, uniquely designed to meet a partner’s specific needs. However, a typical workflow looks like this:
We start by planning the ideal screening campaign for your drug target. Our experienced selection team goes beyond just optimizing screening conditions to also finding the right set of controls and counterscreens to focus discovery efforts on what matters to you. With the right experimental design, we can bias our efforts to locating, e.g. active or allosteric site binders, or already obtain information about binder specificity.
Once selections are performed, our computational chemistry and analytics team goes to work on the data. They’ll take advantage of a deep data analysis pipeline to filter out noise and lock in on the most promising hit compounds. Advanced cheminformatics methods allow us to cluster and visualize the identified chemical space, identifying the most striking compound families and intelligently selecting representative compounds for follow-up.
To help your medicinal chemistry team triage their options and focus only on the most promising candidates, we’ll move ahead to kinetic hit validation. Our proprietary on-DNA biosensor technology lets us screen hit compounds for affinity in your range of interest in only a fraction of the time it would take for conventional large-scale resynthesis and testing. With dissociation constants, on-rates and off-rates, your team can easily pick the most exciting compounds for further development.
From there, we’re still available to offer additional support with compound provision, fragment-linking or whatever it takes to help us achieve success together.
Not sure if you’re ready to launch a full DEL campaign on your target? Or maybe you’re just a do-it-yourself minded scientist. Either way, we’ve got you covered with our research-use DEL kits. Each kit comes with multiple aliquots of a custom-built library containing over 370,000 fragment pairs. Designed to cover a large amount of chemical space and including access to an online data analysis portal, these kits are perfect for testing target tractability or gathering initial data for a grant application. They’re available exclusively through our distributor, MilliporeSigma.
From a straightforward screening campaign to custom library synthesis, we’re ready to be your partner for any DEL project. With our track record of dealmaking with big pharma, small academic groups and everything in between, we’re confident we can find the right solution for any project and any budget.